Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab ...Middle East

BEIJING, SHANGHAI and BOSTON, Oct. 13, 2022 /PRNewswire/ -- Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio's KRAS G12C inhibitor JAB-21822 and Merck's epidermal growth factor receptor...

Hence then, the article about jacobio pharma to collaborate with merck on clinical trial of jab 21822 in combination with cetuximab was published today ( Thursday 13/10/2022 - 04:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab )

Also on site :

• Eli Lilly says next-generation weight loss drug clears crucial obesity trial
• Javier Bardem, Mark Ruffalo, Walter Salles, Isabel Coixet, Annemarie Jacir & Yorgos Lanthimos Sign Anti-Bolloré Letter As Signatures Swell To 3.5K
• Dunkin's 48-Ounce Iced Drink Bucket: How to Get One Before They're Gone